Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone)

Journal of Nuclear Medicine

Volumn 47, Issue 6, 2006, Pages 989-998

  Yuan, Hong ^a   Schroeder, Thies ^a   Bowsher, James E ^a   Hedlund, Laurence W ^a   Wong, Terence ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cu ATSM; PET; Tumor hypoxia

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; CARBONATE DEHYDRATASE IX; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; EOSIN; HEMATOXYLIN; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; OXYGEN; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BREAST ADENOCARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; FIBROSARCOMA; FLUORESCENCE; GLIOMA; HYPOXIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; ANIMAL; CELL HYPOXIA; COMPARATIVE STUDY; FISCHER 344 RAT; METABOLISM; METHODOLOGY; NEOPLASM; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; COPPER RADIOISOTOPES; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THIOSEMICARBAZONES;

EID: 33746089972     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289.
2. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113-117.
3. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
4. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med. 2001;45:183-188.
5. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am. 2005;43:169-187.
6. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
7. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317-326.
8. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
9. 4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655-661.
10. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
11. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
12. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem. 2002;7:249-259.
13. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499-504.
14. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
15. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788-792.
16. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000;60:2018-2024.
17. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol. 2002;352:3-31.
18. Varia MA, Calkins-Adams DP, Rinker LH, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998;71:270-277.
19. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075-7083.
20. Cardenas-Navia LI, Yu D, Braun RD, Brizel DM, Secomb TW, Dewhirst MW. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 2004;64:6010-6017.
21. Cardenas-Navia LI, Braun R, Lewis K, Dewhirst M. Comparison of fluctuations of oxygen tension in FSA, 9L, and R3230AC tumors in rats. Adv Exp Med Biol. 2003;510:7-12.
22. Knoess C, Siegel S, Smith A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging. 2003;30:737-747.
23. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5. Br J Cancer. 1995;72:875-882.
24. 1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer. 1995;72:869-874.
25. Otsu N. A threshold selection method from grey-level histograms. IEEE Trans Syst Man Cybem. 1978;SMC-8:62-66.
26. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 1995;194:795-800.
27. 18F]fluoroetanidazole as a new marker for imaging tumor hypoxia with positron emission tomography. Br J Cancer. 2004;90:2232-2242.
28. 18F-EF5. Eur J Nucl Med Mol Imaging. 2003;30:259-266.
29. Schroeder T, Yuan H, Viglianti BL, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. 2005;65:5163-5171.
30. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.